{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:30:56Z","timestamp":1793212256098,"version":"4.5.0"},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,7,26]],"date-time":"2011-07-26T00:00:00Z","timestamp":1311638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet Comparative Oncology"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:p>Epirubicin is a stereoisomer of doxorubicin that is widely used in human oncology. The purpose of this study was to evaluate the toxicity associated with epirubicin administration in dogs. Three hundred and fifteen treatments were administered to 139 dogs. Patients received between one and seven doses. One hundred and sixteen treatments were associated with toxicity in 81 patients (50 episodes of lethargy, 49 of diarrhoea, 42 of vomiting, 40 of anorexia, 2 hypersensitivity reactions and 2 suspected extravasations). Thirty\u2010six (11%) adverse events resulted in hospitalization in 33 (24%) patients, of which 15 were neutropenic and 9 pyrexic. Mean duration of hospitalization was 3.4 days and 33 patients recovered uneventfully. Owners of 11 patients declined further treatment after toxicity occurred. After 25 treatments associated with toxicity, dose reductions reduced toxicity. The use of prophylactic anti\u2010emetics, gastroprotectants and antibiotics did not reduce the frequency of gastrointestinal toxicity.<\/jats:p>","DOI":"10.1111\/j.1476-5829.2011.00281.x","type":"journal-article","created":{"date-parts":[[2011,7,26]],"date-time":"2011-07-26T18:29:26Z","timestamp":1311704966000},"page":"113-123","source":"Crossref","is-referenced-by-count":19,"title":["Toxicity associated with epirubicin treatments in a large case series of dogs"],"prefix":"10.1111","volume":"10","author":[{"given":"A. M.","family":"Marrington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. R.","family":"Killick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. A.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Blackwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,7,26]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.56.2.6"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(83)80029-2"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.6.818"},{"key":"e_1_2_6_5_2","first-page":"8","article-title":"Comparison of doxorubicin and epirubicin in a clinical trial of dogs with multicentric malignant lymphoma.","volume":"18","author":"Vonderhaar MA.","year":"1994","journal-title":"Veterinary Cancer Society Newsletter"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.12.2148"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.7643"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200210000-00009"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802094229"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.2460\/javma.231.10.1550"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.2002.tb00044.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-070202858-8.50017-8"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","unstructured":"Veterinary Co\u2010operative Oncology Group \u2010 Common Terminology Criteria for Adverse Events (VCOG\u2010CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0.Veterinary and Comparative Oncology2004;2:195\u2013213.","DOI":"10.1111\/j.1476-5810.2004.0053b.x"},{"key":"e_1_2_6_14_2","first-page":"330","volume-title":"Small Animal Clinical Pharmacology and Therapeutics","author":"Barton CL.","year":"2001"},{"key":"e_1_2_6_15_2","first-page":"415","volume-title":"Textbook of Veterinary Internal Medicine","author":"B\u00e9langer MC.","year":"2010"},{"key":"e_1_2_6_16_2","first-page":"2126","volume-title":"Textbook of Veterinary Internal Medicine","author":"Moore AS.","year":"2010"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.1993.tb01033.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2001.tb02328.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-008-0150-8"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.1992.tb03156.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197911)44:5<1588::AID-CNCR2820440508>3.0.CO;2-X"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0928-4680(03)00026-9"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-4431.2008.00346.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2004.tb00162.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5810.2004.00051.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.2460\/javma.1989.195.11.1584","article-title":"Acute and short\u2010term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors.","volume":"195","author":"Ogilvie GK","year":"1989","journal-title":"Journal of the American Veterinary Medical Association"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1385\/CRIAI:24:3:253"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-072160558-6.50014-9"},{"key":"e_1_2_6_29_2","first-page":"289","volume-title":"Cancer Principles and Practice of Oncology","author":"Chu E","year":"2001"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2006.00123.x"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2007.tb02940.x"}],"container-title":["Veterinary and Comparative Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1476-5829.2011.00281.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1476-5829.2011.00281.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T13:32:53Z","timestamp":1741354373000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1476-5829.2011.00281.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,26]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1111\/j.1476-5829.2011.00281.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1476-5829.2011.00281.x","archive":["Portico"],"relation":{},"ISSN":["1476-5810","1476-5829"],"issn-type":[{"value":"1476-5810","type":"print"},{"value":"1476-5829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,26]]}}}